Board of Directors
Board of Directors
Ken Kelley has over 35 years of entrepreneurial, venture capital, operational and technical biotechnology experience. He currently serves on the Board of Directors of Adjuvance Technologies, ID Biologics, Meissa Vaccines, Public Health Vaccines, and publicly held Halozyme Therapeutics. Previously, Mr. Kelley was co-founder, CEO and Chairman of PaxVax. Mr. Kelley was a venture capitalist at K2 BioVentures, Latterell Venture Partners and Institutional Venture Partners (IVP) and has made over 40 biotechnology and medical startup investments. Mr. Kelley was a White House Presidential Executive Fellow from 2016-2017 as well as an Advanced Leadership Initiative (ALI) Fellow at Harvard University from 2015-2016. He earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University.
Pete Leone, MBA, joined SeromYx’s Board of Directors in late 2019. He is life sciences entrepreneur with over twenty-five years of demonstrated success in bio-pharmaceuticals and medical devices. Pete consults with various early stage biotechs in business development and strategic transactions and serves on corporate and not-for-profit Boards. Most recently, Pete led business development efforts for Bicycle Therapeutics as Chief Business Officer.
Previously, Pete was the Vice President of Strategic Business Initiatives at Arrowhead Pharmaceuticals, where he led a $3.7 billion deal with Janssen Pharmaceuticals which included $250 million in upfront cash and equity at a premium. Before that, he was founding CEO or COO at three venture backed companies, including Mersana Therapeutics, where he focused on raising capital and building the company’s platform technology and product pipeline. In his career, Pete negotiated and managed alliances in twenty-four strategic corporate agreements and nine academic technology licenses, including a $670 million collaboration with Amgen and $340 million collaboration with Teva. He has helped several companies from inception to major value creating milestones including validating deals, INDs, clinical development, FDA clearance, payer contracting, patient advocacy, and revenues.
Early in his career, Pete worked in Systems Engineering at General Electric, in marketing at Procter & Gamble, and was a Partner at Corporate Decisions, now part of Mercer. Pete holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business.
Chief Executive Officer
Piers Whitehead has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health. Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies. As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company’s second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr Whitehead holds a BA with honours from Oxford University.
Board Observers and Strategic Advisors
Dr. Armin Spura
Dr. Armin Spura became a Strategic Advisor and Board Observer to SeromYx in Oct 2021. Dr. Spura is the CEO of Crown Bioscience, a leading global pre-clinical and translational contract research organization with a particular focus in oncology. Prior to Crown Bioscience Dr. Spura led the Asia Pacific and Greater China expansion strategy for CareDx, a leader in transplant diagnostics, as well as global product commercialization efforts for Wuxi NextCODE’s data analysis and AI solutions. He has also held multiple leadership positions at Life Technologies and Thermo Fisher Scientific, as General Manager for a China-based joint venture with Da’An Diagnostics, as well as GM for Professional Services for the Genomics Business. Earlier in his career, Dr. Spura helped grow two start-up companies: Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Dr. Spura studied Biochemistry in Germany and received his PhD in Molecular Biology from Brown University.
William Robb joined SeromYx’s Strategic Advisory Board in Oct 2021 and is a partner at Madryn Asset Management, a healthcare focused alternative investment manager. He is also the founding partner of NovaQuest Capital Management, LLC. and investment committee member of NovaQuest Pharma Opportunities Funds III, IV and V and Executive committee member of NovaQuest management company, active in firm growth initiatives, fund-raising and investor relations. From its inception in 2000 through spinout from Quintiles (IQVIA) in 2010 and $2.8b in AUM, across four funds, William has provided leadership of the growth of the NovaQuest business. William has a 20-year transaction history experience in asset-based finance, equity, and structured debt investments with public and private life sciences companies. William holds a B.A. Cum Laude in History from Princeton University and an MBA from Kellogg Graduate School of Management, Northwestern University in Corporate Finance, Strategy and Life Sciences industry management.